Spero Therapeutics Past Earnings Performance
Past criteria checks 4/6
Spero Therapeutics has been growing earnings at an average annual rate of 9.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 48% per year. Spero Therapeutics's return on equity is 21.3%, and it has net margins of 22%.
Key information
9.3%
Earnings growth rate
21.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 48.0% |
| Return on equity | 21.3% |
| Net Margin | 22.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Sizing Up Spero Therapeutics
Oct 15Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why
Aug 11Are Institutions Heavily Invested In Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Shares?
Feb 23Revenue & Expenses BreakdownBeta
How Spero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 104 | 23 | 26 | 0 |
| 30 Sep 23 | 78 | -2 | 26 | 0 |
| 30 Jun 23 | 54 | -10 | 27 | 0 |
| 31 Mar 23 | 54 | -27 | 28 | 0 |
| 31 Dec 22 | 54 | -46 | 36 | 0 |
| 30 Sep 22 | 9 | -102 | 43 | 0 |
| 30 Jun 22 | 10 | -113 | 48 | 0 |
| 31 Mar 22 | 13 | -103 | 49 | 0 |
| 31 Dec 21 | 18 | -90 | 42 | 0 |
| 30 Sep 21 | 17 | -79 | 36 | 0 |
| 30 Jun 21 | 18 | -76 | 30 | 0 |
| 31 Mar 21 | 15 | -74 | 26 | 0 |
| 31 Dec 20 | 9 | -79 | 21 | 0 |
| 30 Sep 20 | 11 | -85 | 18 | 0 |
| 30 Jun 20 | 12 | -84 | 17 | 0 |
| 31 Mar 20 | 12 | -80 | 16 | 0 |
| 31 Dec 19 | 18 | -61 | 16 | 0 |
| 30 Sep 19 | 16 | -47 | 15 | 0 |
| 30 Jun 19 | 12 | -39 | 14 | 0 |
| 31 Mar 19 | 11 | -36 | 14 | 0 |
| 31 Dec 18 | 4 | -42 | 13 | 0 |
| 30 Sep 18 | 3 | -46 | 12 | 0 |
| 30 Jun 18 | 3 | -47 | 12 | 0 |
| 31 Mar 18 | 3 | -50 | 12 | 0 |
| 31 Dec 17 | 2 | -46 | 11 | 0 |
| 30 Sep 17 | 1 | -40 | 11 | 0 |
| 30 Jun 17 | 1 | -35 | 9 | 0 |
| 31 Mar 17 | 0 | -30 | 7 | 0 |
| 31 Dec 16 | 0 | -30 | 7 | 0 |
Quality Earnings: SPRO has high quality earnings.
Growing Profit Margin: SPRO became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPRO has become profitable over the past 5 years, growing earnings by 9.3% per year.
Accelerating Growth: SPRO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SPRO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: SPRO's Return on Equity (21.3%) is considered high.